Abstract
Losartan is a competitive antagonist of the angiotensin II receptor and it is used to treat hypertension. In the seminal Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study, losartan prevented more cardiovascular events and death than atenolol for a similar reduction in blood pressure. It was suggested that losartan may possess pleiotropic effects that could contribute to its clinical benefits. Among the beneficial pharmacological effects of losartan, it has been suggested that losartan could be an effective antithrombotic drug, through competition with the thromboxane receptor due to similarities between the drug and the endogenous thromboxane A2, an established platelet response amplifier.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
